This article was originally published in The Rose Sheet
Japanese beauty firm will respond to high commodity prices and consumer concern over economic downturn by adjusting product prices, launching new products with "high added value" for budget-conscious shoppers, and conducting in-store merchandising initiatives that respond to changes in consumer spending habits, company states in first quarter earnings release issued July 28. Firm's beauty care sales for the quarter decreased 4.6% to $1.33 bil. (¥1=$.009) Intensifying competition in the U.S. market and sluggish consumer spending hampered beauty sales in North America and Europe, though John Frieda and Guhl hair care brands saw "solid" sales in Europe, Kao notes. Japanese beauty sales decreased 1.9% to $986.3 mil. due to lower sales of prestige cosmetics. Kao's net sales fell .4% to $2.98 bil. and net income increased 31.4% to $160.6 mil...
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.